One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Tempest Therapeutics, Inc.
TPST · NCM · Healthcare · Biotechnology
Current price
$0.62
52-week range
$0.62 - $11.13
Market cap
$10.54M
Balance sheet
Distressed
-128.38x Concerning
Net debt $6.78M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
1 Risk
0 rewards · 1 risks
View details ↓What this company does
Tempest Therapeutics, Inc.
Tempest Therapeutics is developing experimental medicines to fight cancer, hoping to make them pills people can take. Their main source of money comes from partnerships with larger drug companies to help fund the expensive process of testing these new treatments, which matters because without that funding, they couldn't continue their research to potentially bring new cancer therapies to patients.
How the company got here
Tempest Therapeutics, Inc. was founded in 2011 and is a clinical-stage biotechnology company focused on developing innovative cancer treatments. The company's core strategy revolves around creating small molecule therapeutics that work by either directly killing cancer cells or by activating the body's own immune system to fight the disease, or a combination of both. Tempest has advanced its research from early stages to later-stage clinical investigations, aiming to address significant unmet medical needs in oncology. The company's journey has involved strategic collaborations and a focus on developing differentiated approaches to cancer therapy.
What it actually does
Tempest Therapeutics develops medicines designed to treat cancer. They focus on creating small molecules, which are tiny chemical compounds that can be taken orally, like a pill. These molecules are engineered to either directly attack cancer cells or to help the patient's immune system recognize and destroy cancer cells. The company is currently in the clinical-stage, meaning its potential medicines are being tested in human trials to see if they are safe and effective.
Amezalpat (TPST-1120)
Amezalpat is one of Tempest's main drug candidates, designed as an oral small molecule that targets a specific protein called PPAR-alpha. This protein is involved in how cancer cells get energy and in creating an environment that helps tumors grow and hide from the immune system. By blocking PPAR-alpha, Amezalpat aims to both directly kill cancer cells and make the tumor environment more favorable for immune cells to attack. Clinical trials have shown promising results, particularly when Amezalpat is used in combination with other standard cancer treatments for liver cancer (hepatocellular carcinoma), showing an improvement in patient survival rates. This drug has received special designations from regulatory agencies, like Fast Track and Orphan Drug, highlighting its potential for treating specific types of cancer where there are limited options.
TPST-1495
TPST-1495 is another key drug candidate from Tempest, developed as an oral small molecule that targets two specific receptors, EP2 and EP4, which are part of the prostaglandin signaling pathway. This pathway can help tumors grow and also suppress the body's immune response against cancer. By blocking both EP2 and EP4 receptors, TPST-1495 aims to inhibit tumor growth and boost the immune system's ability to fight cancer. This drug is being investigated for various types of cancer and has entered Phase 2 clinical trials for conditions like Familial Adenomatous Polyposis (FAP), a genetic disorder that increases the risk of certain cancers. The development of TPST-1495 is supported by collaborations, including with the National Cancer Institute.
In Vivo CAR-T Therapies
Tempest is also developing advanced cell therapies, specifically a type called in vivo CAR-T. Unlike traditional CAR-T therapies where a patient's immune cells are modified in a lab and then infused back, in vivo CAR-T aims to engineer these cells directly within the patient's body. This approach uses novel delivery systems, like lipid nanoparticles carrying genetic instructions, to guide the patient's own T-cells to target and destroy cancer cells. The company is exploring this technology for both cancer and autoimmune diseases, with candidates like TPST-4003 being developed for conditions such as myasthenia gravis and multiple sclerosis, as well as certain blood cancers.
What management is betting on now
Tempest Therapeutics is focusing its strategy on advancing its most promising drug candidates, Amezalpat and TPST-1495, through later-stage clinical trials to demonstrate their safety and effectiveness. Management is also investing in the development of their next-generation in vivo CAR-T therapies, aiming to create a new class of treatments that can be administered more conveniently. The company is pursuing strategic partnerships and external funding to support these development efforts in a capital-efficient manner, aiming to generate significant clinical data before committing substantial internal resources. This approach allows them to explore multiple avenues for treating cancer and other diseases while managing financial risk.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-10.20M
FY2024 Q4
$-10.15M
FY2025 Q1
$-8.04M
FY2025 Q2
$-8.43M
FY2025 Q3
$-6.78M
FY2025 Q4
$-3.57M
FY2026 Q1
$-7.60M
FY2026 Q2
$-2.78M
Revenue
—
Net income
$-5.24M
Diluted EPS
-0.34
Operating cash flow
$-2.78M
Free cash flow
$-2.78M
Fetching…
Sources
Revenue
—
Net income
$-27.70M
Diluted EPS
-2.53
Operating cash flow
$-7.60M
Free cash flow
$-7.60M
Fetching…
Sources
Revenue
—
Net income
$-4.02M
Diluted EPS
-0.31
Operating cash flow
$-3.57M
Free cash flow
$-3.57M
Fetching…
Sources
Revenue
—
Net income
$-3.51M
Diluted EPS
-0.79
Operating cash flow
$-6.78M
Free cash flow
$-6.78M
Fetching…
Sources
Revenue
—
Net income
$-7.87M
Diluted EPS
-2.07
Operating cash flow
$-8.43M
Free cash flow
$-8.43M
Fetching…
Sources
Revenue
—
Net income
$-10.86M
Diluted EPS
-3.16
Operating cash flow
$-8.04M
Free cash flow
$-8.04M
Fetching…
Sources
Revenue
—
Net income
$-13.81M
Diluted EPS
-0.31
Operating cash flow
$-10.15M
Free cash flow
$-10.15M
Fetching…
Sources
Revenue
—
Net income
$-10.56M
Diluted EPS
-0.41
Operating cash flow
$-10.18M
Free cash flow
$-10.20M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $0.62
We couldn't calculate a fair value right now.
Is it drowning in debt?
Distressed
Net debt $6.8M. Interest coverage -128.4x.
Net debt
$6.78M
Interest coverage
-128.38x
Tempest Therapeutics, Inc. is healthier than 0 of 1 peers on balance-sheet leverage.
Distressed
Worse cushion
Baseline
Better cushion
TPST
BASELINE
Tempest Therapeutics, Inc.
Total debt $7.56M Interest coverage -128.38x This is the baseline the peer rows are being compared against.
What you should know
The case for and against TPST
0 Rewards
1 Risk
Rewards
Risks
-
Return on equity was -931.1% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-0.52x
P/B
-9.18x
P/S
—
EV/EBITDA
-0.78x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-931.1%
ROA
-79.4%
Health
Liquidity and balance-sheet strength
Debt / equity
—
Current ratio
0.38x
Quick ratio
0.17x
Total debt
$7.56M
Total cash
$779.00K
Growth
How the business has been compounding
Revenue TTM
$295.00K
Revenue 5Y CAGR
—
EPS TTM
-3.93
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-20.73M
Free CF TTM
$-26.82M
FCF margin
-9,091.5%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—